Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJesus D. Gonzalez‐LugoAAAlexander J. AmbinderKMKrzysztof Mrózek

Discussion

Loading...

Member takes

Overview

Analysis reveals poor survival outcomes in patients with MECOM-rearranged AML treated with hypomethylating agents, suggesting urgent need for better therapies.

Key Points

  • To investigate clinical outcomes in patients with MECOM-rearranged AML treated with hypomethylating agents.
  • Retrospective analysis of 224 patients with MECOM-r AML across multiple US Cancer Centers
  • Assessment of treatment types including venetoclax and hypomethylating agents
  • Analysis of clinical and molecular characteristics, as well as survival outcomes
  • Only 38% achieved composite complete remission (CRc) with varying responses across treatment types
  • Overall survival rates were low, particularly for those treated with hypomethylating agents
  • Multivariable analysis showed worse outcomes associated with chromosome 7 abnormalities and NRAS mutations

Cite This Study

Gonzalez‐Lugo et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6fehttps://doi.org/10.1182/blood-2025-294
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1<i>MECOM</i> fusion partner and bone marrow blast percentage influence outcomes of patients with <i>MECOM</i> rearranged acute myeloid leukaemia2025 · 3 citations
  2. 2Impact of induction regimen and co-mutations on outcomes in AML with myelodysplasia-related changes2025
  3. 3Defining the clinical characteristics and outcomes of adult patients (pts) with 11q23/KMT2A-rearranged Acute Myeloid Leukemia (AML): An analysis from the MARROW consortium2025 · 1 citations
  4. 4Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia2024 · 7 citations
  5. 5Myelodysplasia-related mutation dynamics and outcomes in newly diagnosed (ND) acute myeloid leukemia (AML) treated with low-intensity therapy (LIT).2026